Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 187.23% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating for the company. Morgan Stanley restated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $27.71.

Centessa Pharmaceuticals Trading Down 8.0 %

Shares of Centessa Pharmaceuticals stock opened at $13.23 on Monday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09. The firm has a market capitalization of $1.74 billion, a PE ratio of -8.65 and a beta of 1.54. The firm’s 50-day moving average price is $16.40 and its 200 day moving average price is $16.41.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. On average, sell-side analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 30,526 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the transaction, the insider now directly owns 54,322 shares in the company, valued at approximately $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $15.77, for a total value of $867,350.00. Following the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at approximately $6,771,606.46. This trade represents a 11.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock worth $4,309,568 in the last ninety days. 11.59% of the stock is owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $31,000. GAMMA Investing LLC lifted its holdings in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC boosted its position in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at approximately $171,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.